Automated machine learning for differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma on multiphasic MRI DOI Creative Commons
Rong Hu,

Hui-Zhou Li,

Hannah Horng

и другие.

Scientific Reports, Год журнала: 2022, Номер 12(1)

Опубликована: Май 13, 2022

Abstract With modern management of primary liver cancer shifting towards non-invasive diagnostics, accurate tumor classification on medical imaging is increasingly critical for disease surveillance and appropriate targeting therapy. Recent advancements in machine learning raise the possibility automated tools that can accelerate workflow, enhance performance, increase accessibility artificial intelligence to clinical researchers. We explore use an Tree-Based Optimization Tool leverages a genetic programming algorithm differentiation two common cancers multiphasic MRI. Manual analyses were performed select optimal model, with accuracy 73–75% (95% CI 0.59–0.85), sensitivity 70–75% 0.48–0.89), specificity 71–79% 0.52–0.90) manual optimization, 65–75% 0.43–0.89) 75–79% 0.56–0.90) learning. found performance was similar it could classify hepatocellular carcinoma intrahepatic cholangiocarcinoma comparable radiologists. However, poor subset scans met LI-RADS criteria LR-M. Exploration additional feature selection classifier methods improve LR-M cases as well prospective validation setting are needed prior implementation.

Язык: Английский

Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma <i>via</i> the miRNA-4474-3P-ALOX-15 and EMT axes DOI Open Access

Lei Liu,

Rui Liao, Zhongjun Wu

и другие.

BioScience Trends, Год журнала: 2022, Номер 16(4), С. 267 - 281

Опубликована: Авг. 6, 2022

Recently, the emerging role of circular RNAs (circRNAs) in tumor development and progression has been a topic great interest. Nevertheless, effects hepatic stellate cell (HSC)-derived exosomes hepatocellular carcinoma (HCC) remain unclear. Here, we aim to explore potential effect HSC exosome-derived circWDR25 on aggressiveness HCC. Firstly, microarray analysis circRNAs was performed profile identify differentially expressed derived from activated by HCC cells. Subsequently, roles growth were confirmed through vitro vivo functional experiments. Moreover, RNA pull-down, dual-luciferase reporter assays, fluorescent situ hybridization (FISH) determine interactions circWDR25-miR-4474-3p-ALOX15 loop. Immunohistochemical also tissues peritumoral tissues. We found that overexpressed associated with survival recurrence patients promoted cells both vivo. Mechanistically, exogenous exosomal-derived regulated expression ALOX15 sponging miR-4474-3p ultimately inducing an epithelial-to-mesenchymal transition (EMT) CTLA-4 HSCs PD-L1 In conclusion, facilitated proliferation invasion via circWDR25/miR-4474-3p/ALOX15 EMT axes it cells, thus providing insights into mechanism mediated HSC-derived exosomal circWDR25.

Язык: Английский

Процитировано

28
Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review DOI Open Access

Haowen Tang,

Yinbiao Cao,

Yiping Jian

и другие.

BioScience Trends, Год журнала: 2022, Номер 16(2), С. 130 - 141

Опубликована: Апрель 16, 2022

Hepatocellular carcinoma (HCC) has been the fifth most common malignancy worldwide and is second cause of tumor-related mortality globally. In China, a high proportion patients with HCC present an advanced stage disease, so major challenge to healthcare system substantial socioeconomic burden. The last decade witnessed expansion treatment landscape for HCC. Various approaches have explored as potential conversion therapies Despite controversies, mounting data indicated that successful therapy followed by subsequent surgery achievable in population This safe promising strategy prolong long-term outcomes. Based on preliminary research, this review assembled summarized current clinical experience evidence efficacy

Язык: Английский

Процитировано

23
Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation DOI Creative Commons

Zhengrong Shi,

Yuxin Duan,

Fang Cui

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2023, Номер 42(1)

Опубликована: Май 25, 2023

Abstract Background Efforts to precisely assess tumor-specific T-cell immune responses still face major challenges, and the potential molecular mechanisms mediating hepatocellular carcinoma (HCC) microenvironment imbalance after incomplete radiofrequency ablation (iRFA) are unclear. This study aimed provide further insight into integrated transcriptomic proteogenomic landscape identify a new target involved in HCC progression following iRFA. Methods Peripheral blood matched tissue samples were collected from 10 RFA-treated patients. Multiplex immunostaining flow cytometry used local systemic responses. Differentially expressed genes (DEGs) differentially proteins (DEPs) explored via analyses. Proteinase-3 (PRTN3) was identified these And then, ability of PRTN3 predict overall survival (OS) assessed 70 patients with early recurrence RFA. In vitro CCK-8, wound healing transwell assays conducted observe interactions between Kupffer cells (KCs) induced by PRTN3. The protein levels multiple oncogenic factors signaling pathway components detected western blotting. A xenograft mouse model built tumorigenic effect overexpression on HCC. Results revealed no immediate significant change cell counts periablational tumor tissues 30 min Flow showed significantly increased CD4 + T cells, CD8 CD25 CD127 − Tregs decreased CD16 CD56 natural killer day 5 cRFA ( p < 0.05). Transcriptomics proteomics 389 DEGs 20 DEPs. Pathway analysis that DEP-DEGs mainly enriched immunoinflammatory response, cancer metabolic processes. Among DEP-DEGs, persistently upregulated closely associated OS recurrent KCs may affect migration invasion heat stress-treated cells. promotes growth PI3K/AKT P38/ERK pathways. Conclusions provides comprehensive overview response landscapes milieu iRFA, revealing Trial registration ChiCTR2200055606, http://www.chictr.org.cn/showproj.aspx?proj=32588 .

Язык: Английский

Процитировано

16
A novel immune-associated prognostic signature based on the immune cell infiltration analysis for hepatocellular carcinoma DOI Creative Commons

Xinrong Lin,

Chuan Tian, Fan Pan

и другие.

ONCOLOGIE, Год журнала: 2023, Номер 26(1), С. 91 - 103

Опубликована: Ноя. 8, 2023

Abstract Objectives Immune-related genes (IRGs) in hepatocellular carcinoma (HCC) are significantly associated with both tumor-infiltrating immune cells (TICs) and disease prognosis. Therefore, exploring the correlation between IRGs HCC its related mechanism will provide new evidence for diagnosis treatment of HCC. Methods The current paper analyzed TICs 374 samples retrieved from TCGA-LIHC dataset using ssGSEA divided them according to level cell. A total 177 differentially expressed (DEGs) were by protein-protein interaction (PPI) networks univariate multivariate Cox regression analyses. Results Four (C7, CTSV, MMP1, VCAN) found be indicators prognosis PPI network analyses DEGs, which was independently validated an external dataset. risk model constructed factors dependent on four IRGs. Prognostic subtype infiltrating cells. Conclusions effective identified as novel independent prognostic that correlated tumor infiltration This signature may guide choice immunotherapy

Язык: Английский

Процитировано

15
Anti-hepatocellular carcinoma activity of Sorbaria sorbifolia by regulating VEGFR and c-Met/apoptotic pathway DOI Creative Commons

Zhao-Hua Xu,

Ying Dang,

Yu Dong

и другие.

Journal of Ethnopharmacology, Год журнала: 2024, Номер 324, С. 117758 - 117758

Опубликована: Янв. 20, 2024

Sorbaria sorbifolia (SS) is a traditional Chinese medicine (TCM) that has been employed anti-hepatocellular carcinoma (HCC) for over 2000 years; yet, its underlying mechanism still not fully understood. In this study, we evaluated the anti-HCC effect on freeze-dried powder of water extract SS (FDSS) by inhibiting tumor-induced neovascularization, and promoting apoptosis, elucidated mechanisms. HCC cell lines (HepG2 Huh7 cells) HepG2 xenograft tumors in zebrafish were as vivo vitro models, respectively, to evaluate anti- HCC-indued neovascularization apoptosis. lines, CCK-8 assay, wound-healing transwell circle apoptosis transmission electron microscopy, co-culture assay performed vitro; tumor-zebrafish, tumor growth inhibition hematoxylin eosin (HE) staining, tumor-zebrafish FDSS biological behavior tumor, The expression VEGFR c-Met/apoptotic pathway-related proteins was detected western blotting analysis. Assays c-Met activation conducted assess impact either agonistic or inhibitory roles these receptor proteins. findings from our study revealed effectively suppresses proliferation, migration, invasion cells, well model downregulating p-Met p-AKT decreased associated with including arresting cells cycle at G0/G1phase, increasing apoptotic numbers bodies cancer fluorescence Bcl-2 upregulating Bax, caspase-9, caspase-3 levels. We also found can inhibit HCC-induced regulate VEGFR. Using an agonist inhibitor discovered downregulate protein expression. exerts pro-apoptosis through action pathway.

Язык: Английский

Процитировано

6
Re-exploration of immunotherapy targeting EMT of hepatocellular carcinoma: Starting from the NF-κB pathway DOI Open Access
Shuang Wang, Yan He, Jun Wang

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 174, С. 116566 - 116566

Опубликована: Апрель 16, 2024

Hepatocellular carcinoma (HCC) is the fifth most common malignancies worldwide, and its high morbidity mortality have brought a heavy burden to global public health system. Due concealment of onset, limitation treatment, acquisition multi-drug resistance radiation resistance, treatment HCC cannot achieve satisfactory results. Epithelial mesenchymal transformation (EMT) key process that induces progression, distant metastasis, therapeutic variety malignant tumors, including HCC. Therefore, targeting EMT has become promising tumor immunotherapy method for The NF-κB pathway regulatory EMT. Targeting this shown potential inhibit infiltration, invasion, resistance. At present, there are still some controversies about new ideas combined therapy, which need be further explored. This article reviews progress in improving development cells by exploring mechanism regulating

Язык: Английский

Процитировано

5
Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Creative Commons
Luis A. Rodríguez, Julie A. Schmittdiel, Liyan Liu

и другие.

JAMA Network Open, Год журнала: 2024, Номер 7(7), С. e2421019 - e2421019

Опубликована: Июль 11, 2024

Importance In the US, hepatocellular carcinoma (HCC) has been most rapidly increasing cancer since 1980, and metabolic dysfunction–associated steatotic liver disease (MASLD) is expected to soon become leading cause of HCC. Objective To develop a prediction model for HCC incidence in cohort patients with MASLD. Design, Setting, Participants This prognostic study was conducted among aged at least 18 years MASLD, identified using diagnosis MASLD International Classification Diseases, Ninth Revision (ICD-9) or Statistical Diseases Related Health Problems, Tenth (ICD-10) codes; natural language processing radiology imaging report text, which who had evidence but not formally diagnosed; Dallas Steatosis Index, risk equation that identifies individuals likely have good precision. Patients were enrolled from Kaiser Permanente Northern California, an integrated health delivery system more than 4.6 million members, entry between January 2009 December 2018, follow-up until development, death, termination on September 30, 2021. analysis performed during February 2023 2024. Exposure Data extracted electronic record included routinely measured factors associated Main Outcome Measures The split (70:30) into derivation internal validation sets; extreme gradient boosting used incidence. divided 3 categories, cumulative estimated probability 0.05% less classified as low risk; 0.09%, medium 0.1% greater, high risk. Results A total 1 811 461 (median age [IQR] baseline, 52 [41-63] years; 982 300 [54.2%] female) participated study. During median (range) 9.3 (5.8-12.4) years, 946 developed HCC, rate 0.065 per 1000 person-years. achieved area under curve 0.899 (95% CI, 0.882-0.916) set. At medium-risk threshold, sensitivity 87.5%, specificity 81.4%, number needed screen 406. high-risk 78.4%, 90.1%, 241. Conclusions Relevance 1.8 data discriminate without incident could serve starting point identify may need intervention and/or surveillance.

Язык: Английский

Процитировано

5
Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex DOI Creative Commons

Gu Li,

Xin Jin, Huaiyuan Liang

и другие.

Pharmacological Research, Год журнала: 2023, Номер 192, С. 106789 - 106789

Опубликована: Май 4, 2023

Oral multitarget tyrosine kinase inhibitors (TKIs), such as sorafenib, which suppress tumor cell proliferation and angiogenesis, have been approved to treat patients with hepatocellular carcinoma (HCC). Of note, only approximately 30% of can benefit from TKIs, this population usually acquires drug resistance within 6 months. In study, we intended explore the mechanism associated regulating sensitivity HCC TKIs. We revealed that integrin subunit β 5 (ITGB5) is abnormally expressed in contributes decreased sorafenib. Mechanistically, unbiased mass spectrometry analysis using ITGB5 antibodies interacts EPS15 prevent degradation EGFR cells, activates AKT-mTOR signaling MAPK pathway reduce cells addition, showed CSNK1A1 binds cells. Further study indicated increased protein level through EGFR-AKT-mTOR HCC. Upregulated phosphorylates enhance interaction between activate Thus, identified a positive feedback loop ITGB5-EPS15-EGFR-CSNK1A1 This finding provides theoretical basis for future development therapeutic strategies improve anti-HCC efficacy

Язык: Английский

Процитировано

13
Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma DOI Open Access
Anna Podlasek, Maheeba Abdulla, Dieter C. Bröering

и другие.

Cancers, Год журнала: 2023, Номер 15(13), С. 3347 - 3347

Опубликована: Июнь 26, 2023

Hepatocellular carcinoma (HCC) is responsible for 90% of primary hepatic cancer cases, and its incidence with associated morbidity mortality growing worldwide. In recent decades, there has been a revolution in HCC treatment. There are three main types locoregional therapy: radiofrequency ablation, transarterial chemoembolisation, radioembolisation. This article summarises advances methods.

Язык: Английский

Процитировано

12
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma DOI Open Access
Zijian Yang, Goki Suda,

Osamu Maehara

и другие.

Cancers, Год журнала: 2023, Номер 15(3), С. 593 - 593

Опубликована: Янв. 18, 2023

The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response these therapies, remain underexplored. sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, EGF during HCC were evaluated 46 patients. Patients who experienced PD after CR, PR, or SD evaluated. A total 4, 9, 19, 14 patients showed SD, PD, respectively. Of 32 with disease control, 28 atezolizumab/bevacizumab. Baseline factor levels similar between without control those an objective response. Growth baseline best overall points (BOR) that FGF-19 significantly increased ANG2 decreased at BOR. BOR point VEGF-D compared Summarily, ANG-2 might contribute developing be target molecules salvage therapies.

Язык: Английский

Процитировано

11